MNG39
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PROTEIN_SECRETION+0.286
- PANCREAS_BETA_CELLS+0.205
- ANDROGEN_RESPONSE+0.147
- KRAS_SIGNALING_DN+0.124
- SPERMATOGENESIS+0.114
- HEME_METABOLISM+0.099
- ALLOGRAFT_REJECTION+0.080
- MYC_TARGETS_V1+0.068
- BILE_ACID_METABOLISM+0.045
- PEROXISOME+0.019
Top 10 suppressed
- EPITHELIAL_MESENCHYMAL_TRANSITION-0.430
- NOTCH_SIGNALING-0.424
- ANGIOGENESIS-0.405
- TNFA_SIGNALING_VIA_NFKB-0.393
- G2M_CHECKPOINT-0.338
- CHOLESTEROL_HOMEOSTASIS-0.315
- WNT_BETA_CATENIN_SIGNALING-0.291
- E2F_TARGETS-0.283
- GLYCOLYSIS-0.279
- MYC_TARGETS_V2-0.269
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
6 twins match this tumor's tissue · 4 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | BS_FEPRNEXX | Embryonal tumors | — | 0.822 |
| 2 | R141 | — | — | 0.818 |
| 3 | MDT-AP-2993 | Med | Medulloblastoma | 0.813 |
| 4 | SRR655649 | GTEX | — | 0.810 |
| 5 | SRR934779 | — | — | 0.806 |
| 6 | SRR934740 | — | — | 0.805 |
| 7 | SRR10900001 | — | — | 0.805 |
| 8 | MNG852 | — | — | 0.804 |
| 9 | SAMN03290914 | — | — | 0.803 |
| 10 | BS_ZRM0W01M | low-grade glioma | — | 0.800 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 11 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PROTEIN_SECRETION | 0.286 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.205 | Cobimetinib | — uncovered |
| ANDROGEN_RESPONSE | 0.147 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.124 | Remibrutinib | — uncovered |
| SPERMATOGENESIS | 0.114 | Inavolisib | — uncovered |
| HEME_METABOLISM | 0.099 | Temsirolimus | — uncovered |
| ALLOGRAFT_REJECTION | 0.080 | Idelalisib | — uncovered |
| MYC_TARGETS_V1 | 0.068 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.045 | Inavolisib | — uncovered |
| PEROXISOME | 0.019 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.003 | Inavolisib | — uncovered |